Shokrpour Maryam, Shakiba Elmira, Sirous Ali, Kamali Alireza
Department of Gynecology, Arak University of Medical Sciences, Arak, Iran.
Department of Orology, Arak University of Medical Sciences, Arak, Iran.
J Family Med Prim Care. 2019 Feb;8(2):722-727. doi: 10.4103/jfmpc.jfmpc_18_19.
Postoperative urinary retention (POUR) is defined as a disability in urinary excision after surgery. There are several strategies to prevent POUR, such as tamsulosin, which is a selective antagonist at alpha-1A and alpha-1B-adrenoceptors which reduces the bladder outlet resistance. The aim of this study was to investigate the efficacy of prophylactic tamsulosin in preventing acute urinary retention and other obstructive urinary symptoms following colporrhaphy surgery.
This study was a randomized, double-blind clinical trial. A total of 130 patients who were candidates for colporrhaphy were divided into two groups: the intervention group (65 subjects received 0.4 mg tamsulosin in a single dose at the time of sleeping) and the control group (65 subjects received placebo at the same time as the intervention group). The incidence of acute urinary retention and other obstructive urethral symptoms and the mean urination volume after catheterization were recorded 24 h after operation. Patients' demographic and clinical data were analyzed using SPSS version 20 software using Chi-square and Fisher's tests.
There was a significant difference in the incidence of acute urinary retention, decrease in urine flow diameter, and the mean residual urine volume Post Void Residual (PVR) in the bladder, and the incidence of these symptoms decreased in the tamsulosin recipient group. The incidence of other symptoms of acute urinary retention was not significantly different when compared between both the groups.
It seems that the use of prophylactic tamsulosin is more effective in decreasing the incidence of acute urinary retention, decreasing the PVR in the bladder, and decreasing the diameter of the urine flow in patients after colporrhaphy.
术后尿潴留(POUR)被定义为手术后排尿障碍。有多种预防POUR的策略,如坦索罗辛,它是一种α-1A和α-1B肾上腺素能受体的选择性拮抗剂,可降低膀胱出口阻力。本研究的目的是探讨预防性使用坦索罗辛预防阴道修补术后急性尿潴留及其他梗阻性尿路症状的疗效。
本研究为随机双盲临床试验。总共130例拟行阴道修补术的患者被分为两组:干预组(65例受试者在睡前单次服用0.4mg坦索罗辛)和对照组(65例受试者在与干预组相同时间服用安慰剂)。术后24小时记录急性尿潴留及其他梗阻性尿道症状的发生率以及导尿后的平均排尿量。使用SPSS 20版软件通过卡方检验和费舍尔检验分析患者的人口统计学和临床数据。
急性尿潴留的发生率、尿流直径减小以及膀胱残余尿量(PVR)方面存在显著差异,坦索罗辛治疗组这些症状的发生率降低。两组之间急性尿潴留其他症状的发生率无显著差异。
似乎预防性使用坦索罗辛在降低阴道修补术后患者急性尿潴留的发生率、降低膀胱PVR以及减小尿流直径方面更有效。